Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:ZDHHC20-KCNK1

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: ZDHHC20-KCNK1
	FusionPDB ID: 100793
	FusionGDB2.0 ID: 100793
		Hgene	Tgene
	Gene symbol	ZDHHC20	KCNK1
	Gene ID	253832	3775
	Gene name	zinc finger DHHC-type palmitoyltransferase 20	potassium two pore domain channel subfamily K member 1
	Synonyms	4933421L13Rik\|DHHC-20\|DHHC20	DPK\|HOHO\|K2P1\|K2p1.1\|KCNO1\|TWIK-1\|TWIK1
	Cytomap	13q12.11	1q42.2
	Type of gene	protein-coding	protein-coding
	Description	palmitoyltransferase ZDHHC20probable palmitoyltransferase ZDHHC20zinc finger DHHC domain-containing protein 20zinc finger DHHC-type containing 20	potassium channel subfamily K member 1inward rectifying potassium channel protein TWIK-1potassium channel K2P1potassium channel KCNO1potassium channel, two pore domain subfamily K, member 1potassium inwardly-rectifying channel, subfamily K, member 1
	Modification date	20200313	20200320
	UniProtAcc	.	Q96T54 Main function of 5'-partner protein: FUNCTION: Outward rectifying potassium channel. Produces rapidly activating and non-inactivating outward rectifier K(+) currents.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000320220, ENST00000382466, ENST00000400590, ENST00000415724, ENST00000542645, ENST00000494731, ENST00000422251,	ENST00000366620, ENST00000472190, ENST00000366621,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	14 X 11 X 8=1232	6 X 3 X 5=90
	# samples	16	6
	** MAII score	log2(16/1232*10)=-2.94485844580754 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(6/90*10)=-0.584962500721156 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: ZDHHC20 [Title/Abstract] AND KCNK1 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: ZDHHC20 [Title/Abstract] AND KCNK1 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	ZDHHC20(21965861)-KCNK1(233802341), # samples:1
Anticipated loss of major functional domain due to fusion event.	ZDHHC20-KCNK1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ZDHHC20-KCNK1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ZDHHC20-KCNK1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. ZDHHC20-KCNK1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. ZDHHC20-KCNK1 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	ZDHHC20	GO:0018230	peptidyl-L-cysteine S-palmitoylation	29326245
Hgene	ZDHHC20	GO:0018345	protein palmitoylation	23034182
Tgene	KCNK1	GO:0035725	sodium ion transmembrane transport	21653227
Tgene	KCNK1	GO:0071805	potassium ion transmembrane transport	21653227\|22282804

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr13:21965861/chr1:233802341)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across ZDHHC20 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across KCNK1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst

Tenst

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

Seq length
(transcript)

BP loci
(transcript)

Predicted start
(transcript)

Predicted stop
(transcript)

Seq length
(amino acids)

ENST00000382466

ZDHHC20

chr13

21965861

ENST00000366621

KCNK1

chr1

233802341

2478

840

1495

493

ENST00000415724

ZDHHC20

chr13

21965861

ENST00000366621

KCNK1

chr1

233802341

2469

831

1486

493

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000382466	ENST00000366621	ZDHHC20	chr13	21965861	-	KCNK1	chr1	233802341	+	0.000244341	0.9997557
ENST00000415724	ENST00000366621	ZDHHC20	chr13	21965861	-	KCNK1	chr1	233802341	+	0.000239589	0.99976045

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ZDHHC20-KCNK1

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
ZDHHC20	chr13	21965861	KCNK1	chr1	233802341	831	275	YHCWLVGKNRTTIGYGHTVPLSDGGK
ZDHHC20	chr13	21965861	KCNK1	chr1	233802341	840	275	YHCWLVGKNRTTIGYGHTVPLSDGGK

Top

Potential FusionNeoAntigen Information of ZDHHC20-KCNK1 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

ZDHHC20-KCNK1_21965861_233802341.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-B14:01	IGYGHTVPL	0.9528	0.9532	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-B14:02	IGYGHTVPL	0.9528	0.9532	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-B52:01	TTIGYGHTV	0.3738	0.9774	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C15:06	TTIGYGHTV	0.9992	0.922	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C15:04	TTIGYGHTV	0.999	0.9345	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C03:19	IGYGHTVPL	0.9989	0.9908	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C03:07	TTIGYGHTV	0.9989	0.9834	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C03:08	IGYGHTVPL	0.9986	0.8986	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C04:06	TTIGYGHTV	0.9974	0.8987	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C03:07	IGYGHTVPL	0.9973	0.9854	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C12:12	IGYGHTVPL	0.9972	0.9352	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C15:06	IGYGHTVPL	0.9943	0.92	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C03:19	TTIGYGHTV	0.9891	0.9879	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C06:03	IGYGHTVPL	0.9863	0.9923	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C03:08	TTIGYGHTV	0.9759	0.903	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C08:04	IGYGHTVPL	0.9716	0.9807	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C08:13	IGYGHTVPL	0.9716	0.9807	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C12:04	TTIGYGHTV	0.9467	0.989	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C03:14	IGYGHTVPL	0.9263	0.985	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C06:03	TTIGYGHTV	0.9244	0.9901	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C07:13	IGYGHTVPL	0.8933	0.9217	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C12:12	TTIGYGHTV	0.8592	0.9089	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C02:06	IGYGHTVPL	0.8443	0.9676	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C07:29	IGYGHTVPL	0.8331	0.9297	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C08:03	TTIGYGHTV	0.8289	0.9827	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C01:30	IGYGHTVPL	0.4227	0.9653	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-B51:07	TTIGYGHTV	0.3902	0.8963	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C02:06	TTIGYGHTV	0.3787	0.9773	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C01:17	IGYGHTVPL	0.2581	0.9617	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-B73:01	NRTTIGYGHTV	0.9992	0.8147	8	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C15:02	TTIGYGHTV	0.9995	0.9205	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C15:05	TTIGYGHTV	0.9994	0.9242	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C15:09	TTIGYGHTV	0.999	0.9345	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C03:03	IGYGHTVPL	0.9986	0.9884	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C03:05	IGYGHTVPL	0.9986	0.9186	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C03:04	IGYGHTVPL	0.9986	0.9884	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C03:17	IGYGHTVPL	0.9982	0.9667	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C03:67	IGYGHTVPL	0.998	0.9815	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C16:04	IGYGHTVPL	0.9946	0.9786	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C15:02	IGYGHTVPL	0.9946	0.9199	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C03:02	IGYGHTVPL	0.9941	0.9716	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C03:17	TTIGYGHTV	0.994	0.9548	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C15:05	IGYGHTVPL	0.993	0.9531	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C16:04	TTIGYGHTV	0.9872	0.9597	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C03:06	IGYGHTVPL	0.9863	0.9888	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C03:06	TTIGYGHTV	0.9822	0.9875	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C16:02	TTIGYGHTV	0.9696	0.9916	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C03:03	TTIGYGHTV	0.9536	0.9855	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C03:04	TTIGYGHTV	0.9536	0.9855	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C16:01	IGYGHTVPL	0.9534	0.9797	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-A25:01	TTIGYGHTV	0.9321	0.8412	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C12:03	TTIGYGHTV	0.9083	0.9731	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C08:01	TTIGYGHTV	0.8289	0.9827	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C16:01	TTIGYGHTV	0.785	0.9787	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-B07:13	IGYGHTVPL	0.6402	0.8292	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C12:02	TTIGYGHTV	0.6183	0.958	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C17:01	IGYGHTVPL	0.524	0.9682	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C17:01	TTIGYGHTV	0.4557	0.9742	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C06:08	TTIGYGHTV	0.3188	0.9891	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C02:10	TTIGYGHTV	0.2994	0.9779	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C02:02	TTIGYGHTV	0.2994	0.9779	10	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C01:02	IGYGHTVPL	0.2633	0.9595	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-B48:02	GKNRTTIGY	0.1696	0.8008	6	15
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C01:03	IGYGHTVPL	0.0618	0.9123	12	21
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-B15:53	GKNRTTIGY	0.0614	0.7456	6	15
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-B15:54	GKNRTTIGY	0.0329	0.7174	6	15
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-C15:02	RTTIGYGHTV	0.9908	0.8639	9	19
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	HLA-A68:02	TTIGYGHTVPL	0.9966	0.5443	10	21

Top

Potential FusionNeoAntigen Information of ZDHHC20-KCNK1 in HLA II

ZDHHC20-KCNK1_21965861_233802341.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	DRB1-0901	RTTIGYGHTVPLSDG	9	24
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	DRB1-0903	TIGYGHTVPLSDGGK	11	26
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	DRB1-0903	RTTIGYGHTVPLSDG	9	24
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	DRB1-0904	RTTIGYGHTVPLSDG	9	24
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	DRB1-0905	RTTIGYGHTVPLSDG	9	24
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	DRB1-0906	RTTIGYGHTVPLSDG	9	24
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	DRB1-0906	NRTTIGYGHTVPLSD	8	23
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	DRB1-0907	RTTIGYGHTVPLSDG	9	24
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	DRB1-0908	TIGYGHTVPLSDGGK	11	26
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	DRB1-0908	TTIGYGHTVPLSDGG	10	25
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	840	DRB1-0909	RTTIGYGHTVPLSDG	9	24

Top

Fusion breakpoint peptide structures of ZDHHC20-KCNK1

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
2907	GKNRTTIGYGHTVP	ZDHHC20	KCNK1	chr13	21965861	chr1	233802341	840

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ZDHHC20-KCNK1

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	2907	GKNRTTIGYGHTVP	-7.29174	-7.40514
HLA-B14:02	3BVN	2907	GKNRTTIGYGHTVP	-4.74919	-5.78449
HLA-B52:01	3W39	2907	GKNRTTIGYGHTVP	-5.07451	-5.18791
HLA-B52:01	3W39	2907	GKNRTTIGYGHTVP	-2.86294	-3.89824
HLA-A11:01	4UQ2	2907	GKNRTTIGYGHTVP	-4.62205	-5.65735
HLA-A24:02	5HGA	2907	GKNRTTIGYGHTVP	-11.701	-11.8144
HLA-A24:02	5HGA	2907	GKNRTTIGYGHTVP	-4.6967	-5.732
HLA-B44:05	3DX8	2907	GKNRTTIGYGHTVP	-5.76162	-5.87502
HLA-B44:05	3DX8	2907	GKNRTTIGYGHTVP	-3.98447	-5.01977
HLA-A02:01	6TDR	2907	GKNRTTIGYGHTVP	-2.29826	-3.33356

Top

Vaccine Design for the FusionNeoAntigens of ZDHHC20-KCNK1

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	10	19	TTIGYGHTV	CAACAATAGGTTATGGCCACACCGTGC
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	10	21	TTIGYGHTVPL	CAACAATAGGTTATGGCCACACCGTGCCCTTGT
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	12	21	IGYGHTVPL	TAGGTTATGGCCACACCGTGCCCTTGT
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	6	15	GKNRTTIGY	GAAAAAATAGAACAACAATAGGTTATG
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	8	19	NRTTIGYGHTV	ATAGAACAACAATAGGTTATGGCCACACCGTGC
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	9	19	RTTIGYGHTV	GAACAACAATAGGTTATGGCCACACCGTGC

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	10	25	TTIGYGHTVPLSDGG	CAACAATAGGTTATGGCCACACCGTGCCCTTGTCAGATGGAGGTA
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	11	26	TIGYGHTVPLSDGGK	CAATAGGTTATGGCCACACCGTGCCCTTGTCAGATGGAGGTAAGG
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	8	23	NRTTIGYGHTVPLSD	ATAGAACAACAATAGGTTATGGCCACACCGTGCCCTTGTCAGATG
ZDHHC20-KCNK1	chr13	21965861	chr1	233802341	9	24	RTTIGYGHTVPLSDG	GAACAACAATAGGTTATGGCCACACCGTGCCCTTGTCAGATGGAG

Top

Information of the samples that have these potential fusion neoantigens of ZDHHC20-KCNK1

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
BLCA	ZDHHC20-KCNK1	chr13	21965861	ENST00000382466	chr1	233802341	ENST00000366621	TCGA-FD-A6TF-01A

Top

Potential target of CAR-T therapy development for ZDHHC20-KCNK1

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

ZDHHC20

chr13:21965861

chr1:233802341

ENST00000382466

15_35

242

355.0

Transmembrane

Helical

Hgene

ZDHHC20

chr13:21965861

chr1:233802341

ENST00000382466

170_190

242

355.0

Transmembrane

Helical

Hgene

ZDHHC20

chr13:21965861

chr1:233802341

ENST00000382466

208_231

242

355.0

Transmembrane

Helical

Hgene

ZDHHC20

chr13:21965861

chr1:233802341

ENST00000382466

54_74

242

355.0

Transmembrane

Helical

Hgene

ZDHHC20

chr13:21965861

chr1:233802341

ENST00000400590

15_35

242

454.6666666666667

Transmembrane

Helical

Hgene

ZDHHC20

chr13:21965861

chr1:233802341

ENST00000400590

170_190

242

454.6666666666667

Transmembrane

Helical

Hgene

ZDHHC20

chr13:21965861

chr1:233802341

ENST00000400590

208_231

242

454.6666666666667

Transmembrane

Helical

Hgene

ZDHHC20

chr13:21965861

chr1:233802341

ENST00000400590

54_74

242

454.6666666666667

Transmembrane

Helical

Hgene

ZDHHC20

chr13:21965861

chr1:233802341

ENST00000415724

15_35

242

366.0

Transmembrane

Helical

Hgene

ZDHHC20

chr13:21965861

chr1:233802341

ENST00000415724

170_190

242

366.0

Transmembrane

Helical

Hgene

ZDHHC20

chr13:21965861

chr1:233802341

ENST00000415724

208_231

242

366.0

Transmembrane

Helical

Hgene

ZDHHC20

chr13:21965861

chr1:233802341

ENST00000415724

54_74

242

366.0

Transmembrane

Helical

Tgene

KCNK1

chr13:21965861

chr1:233802341

ENST00000366621

212_224

337.0

Intramembrane

Helical%3B Name%3DPore helix 2

Tgene

KCNK1

chr13:21965861

chr1:233802341

ENST00000366621

225_231

337.0

Intramembrane

Ontology_term=ECO:0000269

Tgene

KCNK1

chr13:21965861

chr1:233802341

ENST00000366621

133_156

337.0

Transmembrane

Helical

Tgene

KCNK1

chr13:21965861

chr1:233802341

ENST00000366621

182_202

337.0

Transmembrane

Helical

Tgene

KCNK1

chr13:21965861

chr1:233802341

ENST00000366621

244_267

337.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to ZDHHC20-KCNK1

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to ZDHHC20-KCNK1

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)